61 results about "Urinary protein" patented technology

The invention provides a traditional Chinese medicine composition for treating nephropathy as well as a preparation method and application thereof, and the anti-renal fibrosis effect is remarkably improved by optimizing a leech extraction process and a novel preparation technology. Animal experiments show that urine protein of model animals can be reduced by 67% and serum creatinine can be reduced by 42% after 12 weeks of continuous administration. Clinical tests prove that the traditional Chinese medicine composition has a definite curative effect on IgA nephropathy, membranous nephropathy and the like, and a new choice is provided for treating chronic kidney diseases.

The application belongs to the field of medicine, and particularly relates to application of a Danzhu Fuguan formula in preparation of a drug for treating idiopathic membranous nephropathy (IMN). The Danzhu Fuguan formula comprises the following raw materials in parts by weight: 25-35 parts of Danshen, 10-15 parts of Baizhu, 25-35 parts of Huangqi, 10-20 parts of Jinyinhua, 10-20 parts of Hujiang, 10-20 parts of Yujin, 10-15 parts of Fuling, 25-35 parts of Yiyiren and 10-15 parts of Qianghuo. Research shows that the Danzhu Fuguan formula can effectively reduce the 24-hour urine protein level of IMN patients, and the 24-hour urine protein level shows a significant downward trend with the extension of the treatment course; according to the IMN clinical efficacy standard, the total remission rate of patients receiving the Danzhu Fuguan formula treatment for 3 months is 37%, the total remission rate of patients receiving the treatment for 6 months is 50%, and the total remission rate of patients receiving the treatment for 12 months reaches 72%, and the remission rate increases significantly with the extension of the treatment course.

1. The name of the design product: storage (urine protein). 2. The use of the design product: for urine protein detection sample storage. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view.

This invention provides a physiological age prediction model that predicts the physiological age of a subject by detecting urinary proteins and metabolites in a urine sample. The aforementioned urinary proteins and metabolites are those that change significantly with age, including one or more selected from the following: cartilage intermediate layer protein (CILP2), collagen Alpha 1 chain (COFA1), myristic acid, 12-methyltridecanoic acid, CN family member 5 (CCN5), Sushi domain-containing protein 5 (SUSD5), procollagen C endopeptidase enhancer 1 (PCOLCE), and L-lactate oxidase (LOX), preferably including all of the aforementioned urinary proteins and metabolites.

The invention discloses an amniotic epithelial cell-derived exosome for treating gestational hypertension and application thereof, and belongs to the technical field of biological medicines. The exosome (hAECs-exos) is obtained by secreting and extracting human amniotic epithelial cells (hAECs), the particle size distribution of the exosome (hAECs-exos) is 30-150 nm, and the exosome (hAECs-exos) expresses exosome specific markers CD9, CD63 and CD81. The invention also provides a preparation method of the exosome. The preparation method comprises the following steps: isolated culture of hAECs, and ultracentrifugal extraction and identification of the exosome. Animal experiments prove that when the exosome is applied to a gestational hypertension disease model animal in an intravenous injection mode, the blood pressure and urine protein level of the gestational hypertension disease model animal can be remarkably reduced, and the fetal rat dysplasia condition is improved. The invention provides a brand-new and effective biological preparation candidate scheme for the treatment of the gestational hypertension disease.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a kidney-tonifying, mass-eliminating and wind-dispelling prescription for preventing and treating diabetic nephropathy as well as a preparation method and application thereof. The kidney-tonifying, mass-eliminating and wind-dispelling prescription consists of astragalus membranaceus, pseudo-ginseng, caulis spatholobi, honeysuckle stem, rhizoma sparganii, common yam rhizome and gordon euryale seed, the seven medicines supplement one another, and the treatment thought of tonifying qi, nourishing blood, dispelling wind, dredging collaterals, eliminating mass and reinforcing kidney is combined on the basis that'deficiency stasis with rheumatism 'is taken as the core pathogenesis of diabetic nephropathy. The traditional Chinese medicine composition is designed aiming at the common clinical manifestations of diabetic nephropathy, such as urine protein rise, limb numbness, edema and renal hypofunction, plays a role in comprehensive regulation and layered intervention, embodies the innovative concept of combining traditional Chinese medicine syndrome differentiation treatment and modern disease spectrum, and has relatively high industrial value.

The application discloses a liposome curcumin composition for assisting in controlling blood sugar and regulating kidney and application thereof, and belongs to the technical field of food and health food. The composition adopts a modular formula design and comprises a basic active component and an optional kidney protection component. The particle size of the liposome curcumin is accurately controlled to be 60-80 nm, the encapsulation rate is greater than or equal to 80%, the ethanol residue is less than or equal to 0.5 ‰, the gastric juice 2h release rate is less than 33%, and the intestinal juice 2h release rate is greater than 80%. By differentially adjusting the component amount, two scenes of simple blood sugar reduction and blood sugar reduction and kidney protection can be adapted, and bidirectional synergy of stable blood sugar regulation and kidney target maintenance can be realized. The application also provides application of the composition in oral liquid, solid beverage, soft capsule and tablet. It is verified through experiments that the bioavailability of the composition is more than 12 times higher than that of conventional curcumin preparation, the postprandial blood sugar peak value is reduced by 25%-30%, the urinary protein excretion rate is reduced by 18%-22%, the safety and compliance are excellent, and the composition is suitable for industrial production.

The invention discloses a folium cortex eucommiae extract and application of the folium cortex eucommiae extract in prevention and treatment of adriamycin nephropathy, and relates to the technical field of medicines, the folium cortex eucommiae extract is prepared from dried folium cortex eucommiae through water extraction, heating at 65 DEG C, ultrasonic assistance and vacuum freeze drying, LC-MS / MS analysis shows that the folium cortex eucommiae extract contains no less than 200 components, the components mainly comprise flavonoids, terpenes and phenylpropanoids, and the content of the flavonoids, the terpenes and the phenylpropanoids is no less than 100%. The folium cortex eucommiae extract has no obvious cytotoxicity to HK-2 and HBZY-1 cells under the concentration of 0-1500mu g / mL, can be used for preparing medicines for preventing and treating adriamycin nephropathy, inhibits kidney cell apoptosis by down-regulating Bax and up-regulating Bcl-2 and obviously reduces the levels of IL-6, IL-1beta and TNF-alpha in serum, and in an animal model, 150-600mg / kg of the folium cortex eucommiae extract is continuously administrated for 21-30 days in an intragastric manner, so that the effect of preventing and treating adriamycin nephropathy is achieved. The traditional Chinese medicine composition can effectively relieve weight loss, reduce urine protein, serum creatinine and urea nitrogen, increase albumin and improve kidney pathological injury, and is suitable for relieving kidney toxicity in a prophylactic or therapeutic mode in subjects receiving adriamycin chemotherapy.

The invention relates to a method for constructing a preeclampsia prediction model by using clinical laboratory data and a related application thereof. Specifically, the preeclampsia risk prediction model is constructed based on a plurality of clinical indexes of pregnant women, a plurality of clinical laboratory data and insulin growth binding factor binding protein 1 and / or placental growth factors. The clinical laboratory data comprises leukocyte count and / or urine protein, and further comprises any one or combination of platelet count, monocyte proportion, glutamic-straw / glutamic-pyruvic transaminase ratio, glutamyltranspeptidase, uric acid and high-density lipoprotein. The constructed preeclampsia risk prediction model can provide a reliable implementation means for early prevention and early treatment of preeclampsia. Meanwhile, the sensitivity of the prediction model is 88.0% when the specificity of early eclampsia is 85.04% and the sensitivity of the prediction model is 62.5% when the specificity of late eclampsia is 85.04% in a complete independent verification set, and the detection performance of the prediction model is higher than that of the current detection performance.

This invention discloses the application of SNCG protein in the auxiliary diagnosis of prostate cancer, belonging to the field of biomedical technology. The application involves using reagents specifically designed to detect SNCG protein expression in biological samples to prepare products for the auxiliary diagnosis of prostate cancer. Through proteomic analysis of urinary proteins from prostate cancer patients and normal men, this invention revealed that the concentration of SNCG protein in the urine of prostate cancer patients was significantly higher than that in the normal male group. Immunohistochemical analysis of paraffin-embedded tissue samples from prostate cancer patients and surrounding normal prostate tissue showed that SNCG protein has a certain expression rate in prostate cancer, and that SNCG protein is also expressed in the basal cells of normal prostate glands, indicating a certain relationship between SNCG protein and the occurrence and development of prostate cancer. This invention can be used to assist in the diagnosis of prostate cancer and difficult cases, thereby improving the diagnosis rate and survival rate of patients.

The invention discloses an application of triptophenol terpene in preparation of a medicine for treating diabetic nephropathy, belongs to the technical field of medicines, is obtained by separating and purifying tripterygium glycosides extract, and is applied as a single active component or a core component in DKD treatment medicines, and solves the problems that a traditional tripterygium glycosides preparation is high in toxicity and uncontrollable in curative effect. The medicine of the triptophenol terpene can obviously inhibit kidney inflammatory factors (IL-6 and TNF-alpha) and fibrosis markers (TGF-beta); the urine protein level is reduced, and the kidney function is improved; and hepatotoxicity and reproductive toxicity risks are avoided.

This invention discloses a biomarker, reagent kit, and system for diagnosing bladder injury secondary to benign prostatic hyperplasia (BPH), relating to the field of biomedical detection technology. The biomarker for diagnosing bladder injury secondary to BPH is characterized in that it includes urinary DAB2 protein. This invention achieves (1) clinical applicability: accurate quantitative assessment of the degree of injury. The most significant clinical value of urinary DAB2 protein lies in its ability to transform traditional subjective bladder injury assessment into an objective quantitative indicator. (2) convenient detection: non-invasive and rapid assessment using urine samples. As a urine detection biomarker, urinary DAB2 protein completely changes the traditional bladder injury assessment's reliance on invasive or expensive examinations such as cystoscopy and CT. (3) clinical decision support: the grading diagnostic value of urinary DAB2 protein is directly translated into clinical decision support capabilities, helping to avoid the clinical dilemma of "overtreatment" or "undertreatment."

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating chronic nephritis and a preparation method and application thereof. The traditional Chinese medicine composition for treating chronic nephritis is prepared from the following raw materials in parts by weight: radix angelicae sinensis, roasted rhizoma atractylodis macrocephalae, radix stephaniae tetrandrae, radix saposhnikoviae, poria cocos, herba epimedii, fructus rosae laevigatae, radix astragali and rhizoma curcumae. After a chronic nephritis patient is treated by the traditional Chinese medicine composition, indexes such as serum creatinine and 24-hour urine protein can be remarkably improved, clinical symptoms are remarkably relieved, and a better product is provided for treating the chronic nephritis patient.

The utility model provides a urine protein collection container, including casing, collection bucket, stirring subassembly and collection mouth. The casing is provided with the hollow inner chamber, is equipped with the door body who can open and close on the casing. The collection bucket is in the inner chamber and can slide out of the casing. The collection bucket upper end is equipped with the liquid inlet, and the liquid inlet is connected with the liquid inlet component. The collection bucket lower end is equipped with the liquid outlet, and the liquid outlet is connected with the liquid outlet component who can open and close. The stirring subassembly is arranged on the collection bucket and one end is inserted into the collection bucket. The collection mouth is set up on the casing and is communicated with the collection bucket by the liquid inlet component, and the collection mouth is provided with the toilet bowl, and the toilet bowl is provided with the splashproof cover or the apron. The urine protein collection container can directly collect urine, and it is more convenient to collect, and it is more beneficial to the detection and preservation of urine.

The invention relates to application of hispidulin or pharmaceutically acceptable salts, esters and solvates thereof in preparation of medicines for treating lupus nephritis. The invention develops a new application of the hispidulin, and proves the treatment effect of the hispidulin on lupus nephritis. Meanwhile, the invention verifies that the hispidulin can obviously improve the renal function indexes (including reducing urine protein, blood urea nitrogen and serum creatinine, increasing serum albumin and improving lipid metabolism) of lupus nephritis, can relieve renal pathological injuries (including reducing glomerular mesangial hyperplasia, basilar membrane thickening, renal tubule dilatation and interstitial inflammation infiltration), and can improve the renal function indexes of lupus nephritis. Kidney immune complex deposition can be reduced (including reduction of deposition of kidney IgG and complement C3), meanwhile, it is found for the first time that angiogenin-like protein 4 (Angptl4) is a key action target for treating lupus nephritis by means of the homospidulin, and the homospidulin plays a kidney protection role by down-regulating Angptl4 expression.

This invention discloses a method for improving a mouse model of ANCA-associated vasculitis induced by anti-GBM antibodies, relating to the field of animal model construction. The method involves subcutaneously injecting mice with 20 μg rMPO on Day 0; administering 10 μg rMPO on Day 7; subcutaneously injecting 250 μg / kg GCSF daily from Day 11 to 15; and injecting 100 μl of goat anti-GBM serum via the tail vein on Day 16 to obtain the improved mouse model. This method improves the existing anti-GBM antibody-induced ANCA-associated vasculitis mouse model by injecting GCSF. This model enhances the disease severity in ANCA-associated vasculitis mice, specifically reflecting the disease in renal pathology and proteinuria, making the differences more obvious and effectively improving the success rate of model establishment.

The invention provides an application of a BCMA-CD19 bispecific CAR (Chimeric Antigen Receptor)-immune cell in the treatment of membranous nephropathy. Specifically, the invention provides a BCMA-CD19 bispecific CAR or a coding nucleic acid thereof, or a carrier thereof, or an application of a CAR-immune cell thereof, and the BCMA-CD19 bispecific CAR or the coding nucleic acid thereof, or the carrier thereof, or the CAR-immune cell thereof is used for (i) preparing a medicine for preventing and / or treating membranous nephropathy (MN); (ii) preparing a medicine for reducing the urine protein level; (iii) preparing a medicine for reducing the PLA2R antibody titer; (iv) preparing a medicine for improving the serum albumin level; and / or (v) preparing a medicine for improving the renal function eGFR level. The invention also provides a method for reducing urine protein level, reducing PLA2R antibody titer, increasing serum albumin level and / or increasing renal function eGFR level and a method for preventing and / or treating membranous nephropathy (MN) by using the BCMA-CD19 bispecific CAR or a coding nucleic acid thereof, or a carrier thereof, or a CAR-immune cell thereof, or a pharmaceutical composition. The BCMA-CD19 bispecific CAR-immune cell provided by the invention has very good safety and effectiveness, and can achieve the purpose that patients with high-risk, recurrent or refractory membranous nephropathy can continuously obtain clinical deep relief treatment.

The invention discloses a Chinese catalpa fruit-based unilateral preparation for eliminating urine protein and application thereof, and belongs to the technical field of traditional Chinese medicine, the active ingredient of the unilateral preparation is extracted from a single medicinal material of Chinese catalpa fruit, and the unilateral preparation can contain pharmaceutically acceptable auxiliary materials. The single preparation can be prepared into four dosage forms of oral liquid, tablets, dripping pills and granules so as to meet different clinical requirements. Animal experiments prove that the single preparation can effectively eliminate urine protein and improve the renal function through four synergistic mechanisms of anti-inflammation, anti-oxidation, improvement of the renal function, protection of podocyte and immunoregulation and diuresis, and is suitable for treating proteinuria accompanied by nephropathy. The preparation provided by the invention has the characteristics of single formula, easy quality control and various dosage forms, and provides a traditional Chinese medicine scheme with an exact curative effect for clinically treating related diseases.

The invention discloses application of polypeptide in preparation of a diabetic nephropathy alleviator, and belongs to the technical field of medicines. The cordyceps sinensis beta-tubulin polypeptide is synthesized by analyzing the structure of the cordyceps sinensis beta-tubulin and selecting amino acid peptide fragments from the 84th site to the 107th site. The apoptosis of the glomerular mesangial cells is induced by using 50 mmol / L of glucose, and meanwhile, the apoptosis of the glomerular mesangial cells induced by high glucose can be relieved by adding the cordyceps sinensis beta-tubulin polypeptide. A treatment test of the cordyceps sinensis beta-tubulin polypeptide on diabetic nephropathy model mice shows that the body mass and fasting blood-glucose levels of the mice in the cordyceps sinensis beta-tubulin polypeptide group are remarkably reduced, the 24-hour urine protein content of the mice is remarkably reduced, and the kidney injury of the mice in the cordyceps sinensis beta-tubulin polypeptide group is remarkably relieved.

The dry type analysis reagent for urine protein detection sequentially comprises an upper supporting layer, a diffusion layer, a reagent layer, a supporting body and a lower supporting layer from top to bottom, the diffusion layer, the reagent layer and the supporting body are sequentially arranged at the middle position between the upper supporting layer and the lower supporting layer from top to bottom, and pores in the two ends of the upper supporting layer and the lower supporting layer are bonded through the middle supporting layer. A sample adding hole and a testing hole are formed in the middle of the upper supporting layer and the middle of the lower supporting layer respectively, the reagent layer is coated on the supporting body, the diffusion layer is coated on the reagent layer, the diffusion layer is a porous diffusion film with various homogeneity, the porosity is 50-85%, the aperture is smaller than or equal to 5 micrometers, and diffusion layer slurry comprises inorganic matter particles, an adhesive, a surfactant and a solvent. The content of the binder per unit square meter is less than 10% of the weight of the inorganic particles. The dry-type analysis reagent has the advantages of excellent anti-interference capability, high test result accuracy, wide measurement range and high clinical application value, meets the requirements of instant diagnosis and field diagnosis, and can be stored for a long time.

The application discloses application of a CK2 inhibitor CX4945 in preparation of a medicine for preventing and / or treating lupus nephritis, and provides the CK2 inhibitor CX4945 which can significantly reduce kidney immune complex and complement C3 deposition of a lupus animal model, effectively reduce a urine protein / cratin ratio, and has no obvious side effect, and can be prepared into a lupus immunotherapy medicine, and simultaneously provides a new combined treatment mode. The medicine can be prepared into an oral medicine, is convenient for treatment, and has high patient compliance.

The application discloses an animal bifidobacterium lactis subsp. RO-1 and products and applications thereof, and belongs to the technical field of microorganisms. The technical problem to be solved is to provide an animal bifidobacterium lactis subsp. capable of preventing the formation and recurrence of kidney stones. The technical solution is to provide an animal bifidobacterium lactis subsp. RO-1, and the preservation number is CGMCC No. 38427. The animal bifidobacterium lactis subsp. RO-1 can regulate urine stone-related indexes, down-regulate urine oxalic acid and urine calcium-related creatinine ratio, weaken the generation inducement of calcium oxalate crystals, reduce urea nitrogen and urine protein creatinine ratio, improve glomerular filtration capacity, reduce nitrogen waste accumulation and protein leakage, reduce the damage of a kidney filtration barrier, repair the structural integrity of a renal tubule, and significantly reduce the kidney stone formation rate.

The application provides a traditional Chinese medicine preparation for treating diabetic nephropathy and a preparation method thereof, and belongs to the technical field of traditional Chinese medicine pharmacy. The traditional Chinese medicine preparation is prepared from traditional Chinese medicinal materials such as angelica, eucommia ulmoides, helicteres angustifolia, broussonetia papyrifera, radix paeoniae suffruticosae, curcuma longa, dendrobium, polygonatum, radix adnati, ligustrum lucidum, ipomoea purpurea, lagerstroemia indica, kochia scoparia, haes, pyrrosia lingua and herba barbatae, and has the effects of nourishing yin and kidney, promoting blood circulation to remove meridian obstruction and clearing heat and removing dampness. The traditional Chinese medicine preparation can up-regulate the expression levels of podocin and nephrin, inhibit inflammatory mediators, improve the blood sugar, urine protein, kidney function and kidney pathological injury of DN rats, provides a new idea for the treatment of diabetic nephropathy, and has a good development and application prospect.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine compound for tonifying kidney, eliminating diseases and dispelling wind for treating diabetic nephropathy. The formula consists of astragalus membranaceus, pseudo-ginseng powder, gordon euryale seed, honeysuckle stem, caulis spatholobi, rhizoma sparganii and common yam rhizome. 19 main active components in the compound are identified through a UPLC-Q-TOF / MS technology, and GSK-3beta and HIF-1alpha are screened as core targets by combining network pharmacology and molecular docking. Animal experiments show that the kidney tonifying, abdominal mass eliminating and wind dispelling prescription can reduce blood sugar and urine protein levels of rats suffering from diabetic nephropathy and down-regulate expression of HIF-1alpha and GSK-3beta, so that kidney energy metabolism and hypoxia state are improved. The compound has the characteristics of multiple targets and systematic regulation and control, establishes a repeatable quality control system, and provides a new strategy for preventing and treating diabetic nephropathy with traditional Chinese medicines.

The invention relates to the technical field of biological analysis, in particular to a nephropathy and staging probability distribution vector extraction method based on real-time endogenous fluorescence imaging data of urine protein gel electrophoresis. Comprising the following steps: acquiring gray value data of each molecular weight zone of urine protein; converting the gray value data into absolute quantitative concentration data of the urine protein component based on a pre-established concentration-gray value standard curve; integrating all concentration data to generate a digital map representing the overall distribution mode of the urine protein, and analyzing the injured part of the kidney glomerulus or / and the kidney tubule according to the digital map; inputting the digital atlas into a pre-trained convolutional neural network model, and extracting a high-dimensional feature vector through forward propagation; probability distribution vectors associated with different nephropathy stages are obtained through calculation of the classifier and serve as prediction information of the stages. Compared with the prior art, through fusion imaging and deep learning, automatic and precise prediction of urine protein whole spectrum analysis and nephropathy and stages thereof is realized.

The invention provides application of a urine protein marker in preparation of a kit for diagnosing esophageal squamous carcinoma. Wherein the urine protein marker is urine Sected photein 1 (SPP1) protein, and researches prove that the SPP1 is highly expressed in urine of esophageal squamous cell carcinoma patients and can be used for detection and auxiliary diagnosis of esophageal squamous cell carcinoma compared with normal control and esophageal squamous cell carcinoma patient groups. According to the invention, the advantages of noninvasive acquisition, large-scale repeated sampling and convenient preservation of the urine sample are exerted, and SPP1 is detected by using the urine sample.

This invention discloses the application of reagents for detecting or overexpressing TMPO in the preparation of diagnostic, early warning, or therapeutic agents for sepsis-induced acute kidney injury (AKI), belonging to the field of molecular biology technology. This invention discovers a novel biomarker for AKI, TMPO, in urinary proteins. Detection based on this biomarker not only boasts high specificity and sensitivity but also utilizes non-invasive urine samples, enabling early diagnosis of AKI. This overcomes the shortcomings of existing diagnostic methods, such as high invasiveness and low early detection rates, providing a reliable biomarker for the early screening and diagnosis of AKI. Furthermore, this invention has developed related agents for treating AKI based on this biomarker, possessing significant clinical application value and patent protection significance.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for preventing and treating lupus nephritis and a preparation method and application thereof. The traditional Chinese medicine composition for preventing and treating lupus nephritis is prepared from the following raw materials: 25 to 35 parts of radix astragali seu hedysari, 8 to 12 parts of radix angelicae sinensis, 8 to 12 parts of radix salviae miltiorrhizae, 25 to 35 parts of herba artemisiae annuae, 12 to 18 parts of caulis sinomenii, 25 to 35 parts of herba centellae, 25 to 35 parts of raw fructus hordei germinatus and 25 to 35 parts of ramulus euonymi. The traditional Chinese medicine has the effects of eliminating and tonifying the whole prescription, not only aims at the superficial symptom of wind-damp heat toxin and blood stasis in an active period, but also considers the base deficiency of kidney deficiency and collateral stasis in a remission period, is matched with the core pathogenesis of deficiency, blood stasis and rheumatism interlaced of lupus nephritis, and has the effects of dispelling wind and eliminating dampness, tonifying kidney and qi, and removing blood stasis and dredging collaterals. Animal experiment results show that the traditional Chinese medicine composition can significantly reduce urine protein, dsDNA and ANA of lupus nephritis mice, and has a good pharmacodynamic effect.

The present application relates to the technical field of biological analysis, and particularly relates to a kidney disease and its staging probability distribution vector extraction method based on real-time endogenous fluorescence imaging data of urine protein gel electrophoresis. The method comprises the following steps: obtaining gray value data of each molecular weight band of urine protein; converting the gray value data into absolute quantitative concentration data of urine protein components based on a pre-established concentration-gray value standard curve; integrating all concentration data to generate a digital atlas representing the overall distribution pattern of urine protein, and analyzing the damaged part of the kidney glomerulus or / and renal tubule according to the digital atlas; inputting the digital atlas into a pre-trained convolutional neural network model, and extracting a high-dimensional feature vector through forward propagation; and obtaining a probability distribution vector associated with different kidney disease stages through a classifier, which is used as prediction information for the staging. Compared with the prior art, the present application realizes the automatic and accurate prediction of urine protein full spectrum analysis and kidney disease and its staging by fusing imaging and deep learning.

A method for constructing a preeclampsia prediction model by using clinical laboratory data and the use thereof. Specifically, the preeclampsia risk prediction model is constructed on the basis of several clinical indexes of pregnant women, several pieces of clinical laboratory data, and insulin-like growth factor-binding protein 1 and / or placental growth factor. The several pieces of clinical laboratory data comprise white blood cell count and / or urine protein, and further comprise any one or a combination of platelet count, monocyte percentage, aspartate aminotransferase / alanine aminotransferase ratio, glutamyl transpeptidase, uric acid and high-density lipoprotein. The constructed preeclampsia risk prediction model can provide a reliable implementation means for early prevention and early treatment of preeclampsia. Moreover, in a fully independent validation set, when the specificity of the prediction model for early-onset preeclampsia is 85.04%, the sensitivity is 88.0%, and when the specificity for late-onset preeclampsia is 85.04%, the sensitivity is 62.5%, outperforming the current detection performance.